BioCryst Pharmaceuticals
Commercializes oral ORLADEYO and develops injectable navenibart for hereditary angioedema.
$9.82
After-hours close0.00 (0.00%)
At close$9.82(−0.51%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 104.74%Insiders 1.71%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 254.16M · Float 214.93M · 84.6% free float
Institutions13F, as of Jun 30, 2026
334 holders · 266.21M shares · 58 new positions · 191 increased · 87 reduced · 40 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 23.89M | 9.40% | +1.24M | Aug 7, 2026 |
| Ra Capital Management, L.P. | 15.83M | 6.23% | 0 | Aug 14, 2026 |
| State Street Corp | 15.19M | 5.98% | +2.98M | Aug 7, 2026 |
| Deerfield Management Company, L.P. (Series C) | 15.10M | 5.94% | +58.4K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 11.36M | 4.47% | +228.5K | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 11.14M | 4.38% | −105.5K | Aug 13, 2026 |
| TCG Crossover Management, LLC | 11.02M | 4.34% | 0 | Aug 14, 2026 |
| Perceptive Advisors LLC | 10.31M | 4.06% | +2.87M | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 8.40% | 17.48M | 13G | Apr 17, 2025 ↗ |
| RA Capital Management, L.P. | 7.30% | 15.30M | 13G | Nov 12, 2025 ↗ |
| Deerfield Mgmt, L.P. | 6.81% | 14.34M | 13G | Feb 12, 2026 ↗ |
| Vanguard Capital Management | 5.16% | 12.96M | 13G | Apr 29, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Jon P. Stonehouse | director | 1.38M | 0.54% | Jun 15, 2026 |
| Charles K. Gayer | officer: President and CCO | 892.5K | 0.35% | Dec 23, 2025 |
| Alane P. Barnes | officer: Chief Legal Officer | 400.7K | 0.16% | May 15, 2026 |
| Helen M. Thackray | officer: Chief R&D Officer | 377.3K | 0.15% | Apr 2, 2025 |
| Babar Ghias | officer: Chief Financial Officer | 268.7K | 0.11% | Dec 19, 2025 |
| Ronald Dullinger | officer: Chief Commercial Officer | 258.4K | 0.10% | Jan 9, 2026 |
| Sandeep Menon | officer: Chief R&D Officer | 205.2K | 0.08% | Apr 7, 2026 |
| Vincent Milano | director | 108.5K | 0.04% | Jun 15, 2026 |
| Nancy J. Hutson | director | 99.1K | 0.04% | Jun 16, 2025 |
| Theresa Heggie | director | 80.6K | 0.03% | Jun 15, 2026 |
7 ten-percent owners hold 7.26M shares by Form 4, outside the officers-and-directors figure above · 23 people have not refiled in the last 18 months (3.01M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| May 18, 2026 | Amy E. McKeedirector | Sale | 11,180 | $8.97 | 31,252 |
| May 13, 2026 | Alane P. Barnesofficer: Chief Legal Officer | Sale | 62,500 | $9.54 | 400,703 |
| Mar 20, 2026 | Theresa Heggiedirector | Sale | 49,933 | $10.11 | 65,352 |
| Mar 16, 2026 | Alane P. Barnesofficer: Chief Legal Officer | Sale | 150,000 | $9.15 | 400,703 |
| Dec 22, 2025 | Alane P. Barnesofficer: Chief Legal Officer | Sale | 21,773 | $7.65 | 398,751 |
| Dec 15, 2025 | Alane P. Barnesofficer: Chief Legal Officer | Sale | 21,210 | $7.65 | 315,726 |
| Dec 3, 2025 | Alane P. Barnesofficer: Chief Legal Officer | Sale | 19,770 | $7.65 | 345,476 |
| Dec 2, 2025 | Alane P. Barnesofficer: Chief Legal Officer | Sale | 50,906 | $7.21 | 365,246 |
| Dec 1, 2025 | Alane P. Barnesofficer: Chief Legal Officer | Sale | 91,004 | $7.10 | 416,152 |
| Nov 13, 2025 | Machelle Sandersdirector | Sale | 9,600 | $7.14 | 30,642 |
CongressHouse and Senate disclosures
Not reported.